In addition to the company's innovation in oxygen therapeutics, NuvOx also has an active pipeline of diagnostics in development. The National Cancer Institute has awarded a $2M Small Business and Innovation Research grant to fund the development of a new strategy to detect pancreatic cancer. For more information, read here.
The FDA has allowed an Investigational New Drug (IND) application to initiate a Phase II clinical trial in 60 stroke patients to proceed to test NuvOx’s investigational drug product, dodecafluoropentane emulsion (DDFPe). Read more...
NuvOx Pharma has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS), for development of a novel syringe sonication device that may allow quick preparation of an investigational drug for oxygen delivery. For more information, read here.
The National Institutes of Health’s National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate a Phase II clinical trial for the investigational drug, NVX-108, in the brain cancer, glioblastoma multiforme (GBM). For more information, read here.
A TV News report on the clinical trial in stroke for NuvOx's drug NVX-208 at the University of Arkansas, interviewing Dr. Bill Culp. Click Here to Watch.